Login to Your Account



Lilly's $960M Colucid buy could bring more M&As in hot migraine space

By Randy Osborne
Staff Writer

Wednesday, January 18, 2017

Eli Lilly and Co.'s takeover of Colucid Pharmaceuticals Inc. for about $960 million calmed some investor frets brought on by patent rulings in the EU and led to speculation about further deals among migraine players.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription